AstraZeneca to Invest $50 Billion in US by 2030

AstraZeneca, the British-Swedish multinational pharmaceutical and biotechnology company, said that it will invest $50 billion in the US by 2030, building on America’s global leadership in medicines manufacturing and R&D.

This investment is expected to create tens of thousands of new, highly skilled direct and indirect jobs across the country powering growth and delivering next generation medicines for patients in America and worldwide.

The cornerstone of this landmark investment is a new multi-billion-dollar US manufacturing facility that will produce drug substances for the company’s innovative weight management and metabolic portfolio, including oral GLP-1, baxdrostat, oral PCSK9 and combination small molecule products. The new state-of-the-art centre will produce small molecules, peptides and oligonucleotides.

This multi-billion-dollar capital investment is in addition to the $3.5 billion announced in November 2024.

The drug substance facility, planned to be in the Commonwealth of Virginia, would be AstraZeneca’s largest single manufacturing investment in the world. The facility will leverage AI, automation, and data analytics to optimise production.

The $50 billion investment across AztraZeneca’s R&D and manufacturing footprint in the US over the next five years also includes expansion of the R&D facility in Gaithersburg, Maryland, state-of-the-art R&D centre in Kendall Square, Cambridge, Massachusetts, next-generation manufacturing facilities for cell therapy in Rockville, Maryland and Tarzana, California, continuous manufacturing expansion in Mount Vernon, Indiana, and specialty manufacturing expansion in Coppell, Texas.

Collectively, these investments will help deliver AstraZeneca’s ambition of reaching $80 billion in total revenue by 2030, of which the company expects 50% would be generated in the US.

Helps in Job Creation

US Secretary of Commerce Howard Lutnick said that for decades, Americans have been reliant on foreign supply of key pharmaceutical products.

“President Donald Trump and our nation’s new tariff policies are focused on ending this structural weakness. We are proud that AstraZeneca has decided to bring substantial pharmaceutical production to our shores. This historic investment is bringing tens of thousands of jobs to the US and will ensure medicine sold in our country is produced right here,” Lutnick added.

Governor Glenn Youngkin, Commonwealth of Virginia, thanked AstraZeneca for choosing Virginia as the cornerstone for this transformational investment. This project will set the standard for the latest technological advancements in pharmaceutical manufacturing, creating hundreds of highly skilled jobs and helping further strengthen the nation’s domestic supply chain.

“Advanced manufacturing is at the heart of Virginia’s dynamic economy, so I am thrilled that AstraZeneca, one of the world’s leading pharmaceutical companies, plans to make their largest global manufacturing investment here in the Commonwealth,” he added.

AstraZeneca CEO Pascal Soriot said that today’s announcement underpins their belief in America’s innovation in biopharmaceuticals and their commitment to the millions of patients who need our medicines in America and globally.

“It will also support our ambition to reach $80 billion in revenue by 2030. I look forward to partnering with Governor Youngkin and his team to work on our largest single manufacturing investment ever. It reflects the Commonwealth of Virginia’s desire to create highly skilled jobs in science and technology, and will strengthen the country’s domestic supply chain for medicines,” Soriot added.